scholarly article | Q13442814 |
P356 | DOI | 10.1158/0008-5472.CAN-07-2488 |
P8608 | Fatcat ID | release_fwgbhwugijag7iy63qyamvi3lq |
P3181 | OpenCitations bibliographic resource ID | 1548992 |
P698 | PubMed publication ID | 18199536 |
P5875 | ResearchGate publication ID | 5651066 |
P2093 | author name string | Wang J | |
Yang H | |||
He L | |||
Coppola D | |||
Nicosia SV | |||
Kruk PA | |||
Cheng JQ | |||
Kong W | |||
Zhao JJ | |||
O'Donnell JD | |||
Wenham RM | |||
P2860 | cites work | AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance | Q47971254 |
P433 | issue | 2 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | ovarian cancer | Q172341 |
cisplatin | Q412415 | ||
microRNA expression | Q60681249 | ||
P304 | page(s) | 425-33 | |
P577 | publication date | 2008-01-15 | |
P1433 | published in | Cancer Research | Q326097 |
P1476 | title | MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN | |
P478 | volume | 68 |
Q26746952 | A Comparative Analysis of Genetic and Epigenetic Events of Breast and Ovarian Cancer Related to Tumorigenesis |
Q34072975 | A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk |
Q38637596 | A Macro View of MicroRNAs: The Discovery of MicroRNAs and Their Role in Hematopoiesis and Hematologic Disease |
Q37529831 | A Pilot Study of Circulating MicroRNA-125b as a Diagnostic and Prognostic Biomarker for Epithelial Ovarian Cancer |
Q24632651 | A coding-independent function of gene and pseudogene mRNAs regulates tumour biology |
Q83575970 | A commentary on MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma |
Q35547227 | A computational approach to identifying gene-microRNA modules in cancer |
Q33634277 | A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer |
Q34985302 | A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer |
Q34167137 | A microRNA survival signature (MiSS) for advanced ovarian cancer. |
Q51354687 | A simple method for incorporating dynamic effects of intronic miRNA mediated regulation. |
Q36074982 | Aberrant expression of microRNAs in gastric cancer and biological significance of miR-574-3p |
Q37124069 | Adenomatous polyposis coli (APC) regulates miR17-92 cluster through β-catenin pathway in colorectal cancer |
Q37386222 | Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer |
Q39501335 | Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). |
Q24648360 | Altered microRNA Expression Patterns in Hepatoblastoma Patients |
Q47838011 | Altered microRNA expression patterns during the initiation and promotion stages of neonatal diethylstilbestrol-induced dysplasia/neoplasia in the hamster (Mesocricetus auratus) uterus |
Q36944254 | An array-based analysis of microRNA expression comparing matched frozen and formalin-fixed paraffin-embedded human tissue samples |
Q39400566 | An electrochemical signal 'off-on' sensing platform for microRNA detection |
Q38060281 | An emerging role for microRNAs in NF1 tumorigenesis |
Q35477129 | An integrated network of microRNA and gene expression in ovarian cancer |
Q35672216 | An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription |
Q98164950 | Analysis of conserved miRNAs in cynomolgus macaque genome using small RNA sequencing and homology searching |
Q34365873 | Annexin A4 induces platinum resistance in a chloride-and calcium-dependent manner |
Q35574298 | Anti-fibrotic Role of miR-214 in Thioacetamide-induced Liver Cirrhosis in Rats |
Q99551767 | Antitumor effects and molecular mechanisms of action of natural products in ovarian cancer |
Q37783931 | Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy |
Q36590184 | Blood microRNAs in low or no risk ischemic stroke patients |
Q35273614 | By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy. |
Q37372564 | CHO microRNA engineering is growing up: recent successes and future challenges |
Q37152727 | Candidate microRNA biomarkers in human epithelial ovarian cancer: systematic review profiling studies and experimental validation |
Q34391443 | Cardio-miRNAs and onco-miRNAs: circulating miRNA-based diagnostics for non-cancerous and cancerous diseases |
Q37316664 | Cell-Free microRNA-214 From Urine as a Biomarker for Non-Muscle-Invasive Bladder Cancer. |
Q34089685 | Cellular Responses to Cisplatin‐Induced DNA Damage |
Q38206278 | Cellular communication via microparticles: role in transfer of multidrug resistance in cancer |
Q34055428 | Cellular stress induced alterations in microRNA let-7a and let-7b expression are dependent on p53 |
Q21245716 | Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy |
Q45077649 | Characterization of disease progression in ovarian cancer by utilizing 'chemograms' of ovarian cancer stem cells |
Q38490114 | Circulating MicroRNAs as potential biomarkers for alcoholic steatohepatitis |
Q35562931 | Circulating microRNAs as potential biomarkers for endometriosis |
Q36105474 | Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes |
Q35735278 | Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer. |
Q35204609 | Clinically relevant microRNAs in ovarian cancer |
Q35904981 | Clinico-Pathological Association of Delineated miRNAs in Uveal Melanoma with Monosomy 3/Disomy 3 Chromosomal Aberrations |
Q35116221 | Clinicopathological significance of microRNA-214 in gastric cancer and its effect on cell biological behaviour |
Q39218148 | Comparative study of microRNA regulation on FOXL2 between adult-type and juvenile-type granulosa cell tumours in vitro. |
Q55385529 | Comparative transcriptome analysis to investigate the potential role of miRNAs in milk protein/fat quality. |
Q37097112 | Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance |
Q86506652 | Computational approaches for identifying cancer miRNA expressions |
Q33492595 | Computational identification of hepatitis C virus associated microRNA-mRNA regulatory modules in human livers |
Q35010110 | Control of the rescue and replication of Semliki Forest virus recombinants by the insertion of miRNA target sequences |
Q89529824 | Cooperation between SS18-SSX1 and miR-214 in Synovial Sarcoma Development and Progression |
Q36350416 | Coordinated loss of microRNA group causes defenseless signaling in malignant lymphoma. |
Q34416068 | Costimulation-dependent expression of microRNA-214 increases the ability of T cells to proliferate by targeting Pten. |
Q37195490 | Cross talk between miR-214 and PTEN attenuates glomerular hypertrophy under diabetic conditions |
Q51442271 | Crosstalk between the vitamin D receptor (VDR) and miR-214 in regulating SuFu, a hedgehog pathway inhibitor in breast cancer cells. |
Q38717405 | Curcumin suppresses cisplatin resistance development partly via modulating extracellular vesicle-mediated transfer of MEG3 and miR-214 in ovarian cancer |
Q36517492 | Current status and implications of microRNAs in ovarian cancer diagnosis and therapy |
Q38711390 | Current status on microRNAs as biomarkers for ovarian cancer |
Q35774040 | DNA methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression |
Q34321166 | Damage associated molecular pattern molecule-induced microRNAs (DAMPmiRs) in human peripheral blood mononuclear cells |
Q37305438 | Decreased expression of miR-125b and miR-100 in oral cancer cells contributes to malignancy |
Q36553118 | Deregulation of miR-21 and miR-155 and their putative targets after silibinin treatment in T47D breast cancer cells |
Q41837402 | Deregulation of the miRNAs expression in cervical cancer: human papillomavirus implications |
Q47593475 | Diagnostic and Prognostic Biomarkers in ovarian cancer and the potential roles of cancer stem cells - An updated review |
Q53659259 | Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients. |
Q38928861 | Direct detection of microRNA based on plasmon hybridization of nanoparticle dimers |
Q46314432 | Distinctive microRNA expression signatures in proton-irradiated mice |
Q35377371 | Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia |
Q39521543 | Down-regulated miRNA-214 induces a cell cycle G1 arrest in gastric cancer cells by up-regulating the PTEN protein |
Q33677872 | Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression. |
Q24655144 | Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1 |
Q37364111 | Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-κB signaling. |
Q52676612 | Downregulation of MicroRNA-455-3p Links to Proliferation and Drug Resistance of Pancreatic Cancer Cells via Targeting TAZ. |
Q39074816 | Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly |
Q38699390 | Downregulation of miR-193a-3p inhibits cell growth and migration in renal cell carcinoma by targeting PTEN. |
Q39809297 | Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer |
Q44104084 | Downregulation of miR-195 correlates with lymph node metastasis and poor prognosis in colorectal cancer |
Q39117322 | Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells |
Q38712331 | Downregulation of miR-33a-5p in Hepatocellular Carcinoma: A Possible Mechanism for Chemotherapy Resistance |
Q34806765 | Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis. |
Q90465480 | Dysregulated microRNA expression profiles in gastric cancer cells with high peritoneal metastatic potential |
Q39735817 | Dysregulation of kallikrein-related peptidases in renal cell carcinoma: potential targets of miRNAs |
Q37040599 | Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer |
Q21198870 | Dysregulation of miR-15a and miR-214 in human pancreatic cancer |
Q41034799 | Dysregulation of microRNA-214 and PTEN contributes to the pathogenesis of hypoxic pulmonary hypertension |
Q52331347 | ELLPMDA: Ensemble Learning and Link Prediction for miRNA-Disease Association prediction. |
Q26781912 | EMT-Inducing Molecular Factors in Gynecological Cancers |
Q34168267 | ER stress negatively modulates the expression of the miR-199a/214 cluster to regulates tumor survival and progression in human hepatocellular cancer |
Q36520143 | Early detection biomarkers for ovarian cancer |
Q42722759 | Effect of phosphatase and tensin homology deleted on chromosome 10 (PTEN) gene transfection on reversal of multidrug resistance in K562/ADM cells |
Q92945442 | Effects of miR-34b/miR-892a Upregulation and Inhibition of ABCB1/ABCB4 on Melatonin-Induced Apoptosis in VCR-Resistant Oral Cancer Cells |
Q90636051 | Efficient miRNA Inhibitor Delivery with Graphene Oxide-Polyethylenimine to Inhibit Oral Squamous Cell Carcinoma |
Q98238826 | Efficient miRNA Inhibitor with GO-PEI Nanosheets for Osteosarcoma Suppression by Targeting PTEN |
Q33621526 | Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance |
Q34526484 | Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer |
Q42176783 | Elucidating the mechanism of miRNA-214 in the regulation of gingival carcinoma |
Q39123447 | Enrichment of ovarian cancer stem-like cells is associated with epithelial to mesenchymal transition through an miRNA-activated AKT pathway |
Q90682389 | Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives |
Q51168142 | Epigenetic Downregulation of PTEN in Gallbladder Cancer. |
Q33615837 | Epigenetic control of autophagy by microRNAs in ovarian cancer |
Q37853945 | Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer--a review |
Q38544386 | Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer |
Q34874813 | Epigenetic regulation of cancer-associated genes in ovarian cancer |
Q38730550 | Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma |
Q33572313 | Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer |
Q34305438 | Epigenetic therapies as a promising strategy for overcoming chemoresistance in epithelial ovarian cancer |
Q90266694 | Epigenetically altered miR‑193a‑3p promotes HER2 positive breast cancer aggressiveness by targeting GRB7 |
Q37737449 | Epigenetics of ovarian cancer: from the lab to the clinic |
Q35636575 | Epigenomics and ovarian carcinoma. |
Q35711392 | Epigenomics of ovarian cancer and its chemoprevention |
Q36923079 | Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2. |
Q33561359 | Evaluation of Plasma MicroRNAs as Diagnostic and Prognostic Biomarkers in Pancreatic Adenocarcinoma: miR-196a and miR-210 Could Be Negative and Positive Prognostic Markers, Respectively |
Q33980036 | Evidence for the complexity of microRNA-mediated regulation in ovarian cancer: a systems approach. |
Q81549199 | Exosomal microRNAs step into the biomarker arena |
Q49886928 | Exosomes Serve as Nanoparticles to Deliver Anti-miR-214 to Reverse Chemoresistance to Cisplatin in Gastric Cancer |
Q93369514 | Exposure of the extracellular matrix and colonization of the ovary in metastasis of fallopian-tube-derived cancer |
Q38996872 | Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features |
Q37356540 | FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells |
Q24610158 | Flexible and versatile as a chameleon-sophisticated functions of microRNA-199a |
Q26797287 | Focus on PTEN Regulation |
Q34450467 | Follicular dendritic cell-dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion-mediated Bim down-regulation through induction of microRNA-181a |
Q33658229 | Frequent downregulation of miR-34 family in human ovarian cancers |
Q38228678 | From miRNA regulation to miRNA-TF co-regulation: computational approaches and challenges |
Q38951546 | Functional analysis of miR-34c as a putative tumor suppressor in high-grade serous ovarian cancer |
Q41082813 | Functional screen analysis reveals miR-3142 as central regulator in chemoresistance and proliferation through activation of the PTEN-AKT pathway in CML. |
Q34669761 | Gain-of-function microRNA screens identify miR-193a regulating proliferation and apoptosis in epithelial ovarian cancer cells |
Q33433032 | Gemcitabine Plus Vinorelbine as Second-Line Therapy in Patients With Metastatic Esophageal Cancer Previously Treated With Platinum-Based Chemotherapy |
Q34252833 | Gene regulation is governed by a core network in hepatocellular carcinoma. |
Q50059680 | Genetic ablation of Rbm38 promotes lymphomagenesis in the context of mutant p53 by downregulating PTEN. |
Q26769604 | Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy |
Q34227531 | Genetic polymorphisms in pre-microRNA genes as prognostic markers of colorectal cancer |
Q37730044 | Genetic variants in MicroRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response |
Q38256465 | Genomic alterations as mediators of miRNA dysregulation in ovarian cancer. |
Q36657641 | Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer |
Q47171648 | Ginsenoside Rg3 Decreases Fibrotic and Invasive Nature of Endometriosis by Modulating miRNA-27b: In Vitro and In Vivo Studies |
Q47646794 | Global DNA methylation analysis reveals miR-214-3p contributes to cisplatin resistance in pediatric intracranial nongerminomatous malignant germ cell tumors |
Q28478564 | Global analysis of DNA methylation by Methyl-Capture sequencing reveals epigenetic control of cisplatin resistance in ovarian cancer cell |
Q35089974 | Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker |
Q47385628 | HDAC inhibitor suppresses proliferation and invasion of breast cancer cells through regulation of miR-200c targeting CRKL. |
Q34115364 | HIV-1 Nef and KSHV oncogene K1 synergistically promote angiogenesis by inducing cellular miR-718 to regulate the PTEN/AKT/mTOR signaling pathway |
Q92616938 | HOTAIR/miR-214-3p/FLOT1 axis plays an essential role in the proliferation, migration, and invasion of hepatocellular carcinoma |
Q36242420 | High Throughput Sequencing of Extracellular RNA from Human Plasma |
Q92288085 | High expression of NFAT2 contributes to carboplatin resistance in lung cancer |
Q35105646 | High expression of miR-214 is associated with a worse disease-specific survival of the triple-negative breast cancer patients. |
Q37337788 | High fat diet induced obesity alters ovarian phosphatidylinositol-3 kinase signaling gene expression |
Q28476426 | Holoclone forming cells from pancreatic cancer cells enrich tumor initiating cells and represent a novel model for study of cancer stem cells |
Q24321272 | Human polynucleotide phosphorylase selectively and preferentially degrades microRNA-221 in human melanoma cells |
Q38857270 | Hybrid-polymerase chain reaction to identify novel target genes of miR-134 in paclitaxel resistant human ovarian carcinoma cells |
Q33504873 | Identification and characterization of miRNAs expressed in the bovine ovary |
Q37006170 | Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. |
Q37215410 | Identification of a Novel lincRNA-p21-miR-181b-PTEN Signaling Cascade in Liver Fibrosis. |
Q35326035 | Identification of a microRNA signature in renal fibrosis: role of miR-21. |
Q34069581 | Identification of a microRNA signature of renal ischemia reperfusion injury |
Q35744525 | Identification of a novel miRNA from the ovine ovary by a combinatorial approach of bioinformatics and experiments |
Q42276827 | Identification of common oncogenic and early developmental pathways in the ovarian carcinomas controlling by distinct prognostically significant microRNA subsets |
Q54962236 | Identification of core aberrantly expressed microRNAs in serous ovarian carcinoma. |
Q35767380 | Identification of links between small molecules and miRNAs in human cancers based on transcriptional responses |
Q34838128 | Identification of miRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis |
Q39137785 | Identification of microRNAs and mRNAs associated with multidrug resistance of human laryngeal cancer Hep-2 cells |
Q34368313 | Identifying functional miRNA-mRNA regulatory modules with correspondence latent dirichlet allocation |
Q37497803 | Identifying miRNAs, targets and functions. |
Q21199589 | Identifying microRNA/mRNA dysregulations in ovarian cancer |
Q34366411 | Identifying multi-layer gene regulatory modules from multi-dimensional genomic data |
Q27016123 | Impact of Nutrition on Non-Coding RNA Epigenetics in Breast and Gynecological Cancer |
Q28539562 | Impact of ketamine on learning and memory function, neuronal apoptosis and its potential association with miR-214 and PTEN in adolescent rats |
Q33903223 | Implication of microRNAs in drug resistance for designing novel cancer therapy |
Q39304895 | Induction of microRNA-214-5p in human and rodent liver fibrosis |
Q91761695 | Inhibition of miR-214-3p Aids in Preventing Epithelial Ovarian Cancer Malignancy by Increasing the Expression of LHX6 |
Q38858897 | Inhibition of microRNA-214 ameliorates hepatic fibrosis and tumor incidence in platelet-derived growth factor C transgenic mice |
Q36755634 | Inhibition of p38 mitogen-activated protein kinase alters microRNA expression and reverses epithelial-to-mesenchymal transition |
Q42723115 | Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma |
Q38152325 | Involvement of autophagy in cervical, endometrial and ovarian cancer |
Q21198790 | Involvement of autophagy in ovarian cancer: a working hypothesis |
Q39615360 | Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line |
Q39371337 | Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells |
Q55038905 | Involvement of non-coding RNAs in chemotherapy resistance of ovarian cancer. |
Q28486480 | Klotho sensitizes human lung cancer cell line to cisplatin via PI3k/Akt pathway |
Q37500162 | Knockdown of miR-214 promotes apoptosis and inhibits cell proliferation in nasopharyngeal carcinoma |
Q34360216 | LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival |
Q24653755 | Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression |
Q93002451 | Let-7 as biomarker, prognostic indicator, and therapy for precision medicine in cancer |
Q39134240 | Let-7b expression determines response to chemotherapy through the regulation of cyclin D1 in glioblastoma |
Q38267349 | Light-regulated microRNAs |
Q58804953 | LncRNA PVT1 promotes ovarian cancer progression by silencing miR-214 |
Q92795407 | Long Non-Coding RNA NONHSAT076754 Promotes Invasion and Metastasis in Epithelial Ovarian Cancer |
Q35172618 | Long non-coding RNAs (LncRNA) regulated by transforming growth factor (TGF) β: LncRNA-hit-mediated TGFβ-induced epithelial to mesenchymal transition in mammary epithelia |
Q37636621 | Loss of MYC and E-box3 binding contributes to defective MYC-mediated transcriptional suppression of human MC-let-7a-1~let-7d in glioblastoma |
Q93048655 | Loss of PTEN in Fallopian Tube Epithelium Results in Multicellular Tumor Spheroid Formation and Metastasis to the Ovary |
Q84079294 | Loss of heterozygosity proximal to the M6P/IGF2R locus is predictive for the presence of disseminated tumor cells in the bone marrow of ovarian cancer patients before and after chemotherapy |
Q89641392 | Loss of phosphatase activity in PTEN (phosphatase and tensin homolog deleted on chromosome ten) results in endometrial carcinoma in humans: An in-silico study |
Q50859800 | Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma. |
Q37806613 | Metastamirs: a stepping stone towards improved cancer management |
Q39675974 | MiR-125b targets BCL3 and suppresses ovarian cancer proliferation |
Q37584834 | MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression |
Q38359431 | MiR-139-5p: promising biomarker for cancer |
Q39210882 | MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine |
Q24632636 | MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer |
Q91876236 | MiR-186 bidirectionally regulates cisplatin sensitivity of ovarian cancer cells via suppressing targets PIK3R3 and PTEN and upregulating APAF1 expression |
Q35854007 | MiR-191 inhibits TNF-α induced apoptosis of ovarian endometriosis and endometrioid carcinoma cells by targeting DAPK1. |
Q47569619 | MiR-199a suppresses prostate cancer paclitaxel resistance by targeting YES1. |
Q33688560 | MiR-214 and N-ras regulatory loop suppresses rhabdomyosarcoma cell growth and xenograft tumorigenesis |
Q41549238 | MiR-214 inhibits cell migration, invasion and promotes the drug sensitivity in human cervical cancer by targeting FOXM1 |
Q28569223 | MiR-214 promotes the alcohol-induced oxidative stress via down-regulation of glutathione reductase and cytochrome P450 oxidoreductase in liver cells |
Q37028111 | MiR-214 regulate gastric cancer cell proliferation, migration and invasion by targeting PTEN. |
Q64092312 | MiR-214 sensitizes human colon cancer cells to 5-FU by targeting Hsp27 |
Q38807890 | MiR-214 suppressed ovarian cancer and negatively regulated semaphorin 4D. |
Q34409807 | MiR-214 targets β-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma. |
Q38940572 | MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1. |
Q37045562 | MiR-24 enhances radiosensitivity in nasopharyngeal carcinoma by targeting SP1. |
Q39681268 | MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells |
Q41926584 | MiR-3120 is a mirror microRNA that targets heat shock cognate protein 70 and auxilin messenger RNAs and regulates clathrin vesicle uncoating |
Q37301794 | MiR-320a inhibits gastric carcinoma by targeting activity in the FoxM1-P27KIP1 axis |
Q36413483 | MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1 |
Q37729740 | MiR-519d represses ovarian cancer cell proliferation and enhances cisplatin-mediated cytotoxicity in vitro by targeting XIAP. |
Q38996307 | MiR-718 represses VEGF and inhibits ovarian cancer cell progression |
Q34036679 | MiRNA as potential biomarkers and therapeutic targets for gastric cancer. |
Q45942073 | MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma. |
Q39413698 | MiRNA-21: a biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer |
Q36685095 | MiRNA-429 suppresses the growth of gastric cancer cells in vitro |
Q34808577 | MiRNAs as Biomarkers for Management of Patients With Colorectal Cancer |
Q37297742 | MiRNAs which target CD3 subunits could be potential biomarkers for cancers |
Q38905681 | MiRNAs-mediated cisplatin resistance in breast cancer |
Q35223019 | Micro-RNA378 (miR-378) regulates ovarian estradiol production by targeting aromatase |
Q38183485 | Micro-RNAs and ovarian cancer: the state of art and perspectives of clinical research |
Q27005811 | Micro-RNAs as potential new molecular biomarkers in oncology: have they reached relevance for the clinical imaging sciences? |
Q37981156 | MicroRNA Control of Invasion and Metastasis Pathways |
Q92876704 | MicroRNA Signature in Human Normal and Tumoral Neural Stem Cells |
Q37295059 | MicroRNA and cancer--focus on apoptosis |
Q37751868 | MicroRNA and drug resistance |
Q35631669 | MicroRNA changes in human arterial endothelial cells with senescence: relation to apoptosis, eNOS and inflammation. |
Q33344505 | MicroRNA expression and identification of putative miRNA targets in ovarian cancer |
Q36253778 | MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features |
Q50014321 | MicroRNA expression profiles in non‑epithelial ovarian tumors. |
Q39544815 | MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance |
Q53280271 | MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer. |
Q38336334 | MicroRNA fate upon targeting with anti-miRNA oligonucleotides as revealed by an improved Northern-blot-based method for miRNA detection. |
Q35908632 | MicroRNA genes and their target 3'-untranslated regions are infrequently somatically mutated in ovarian cancers |
Q64883178 | MicroRNA in Ovarian Cancer: Biology, Pathogenesis, and Therapeutic Opportunities. |
Q35055772 | MicroRNA in the ovary and female reproductive tract |
Q24649254 | MicroRNA miR-155 is a biomarker of early pancreatic neoplasia |
Q36318784 | MicroRNA miR-214 regulates ovarian cancer cell stemness by targeting p53/Nanog |
Q37388413 | MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer |
Q34694027 | MicroRNA profile of paclitaxel-resistant serous ovarian carcinoma based on formalin-fixed paraffin-embedded samples |
Q33508232 | MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary |
Q35064852 | MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sézary syndrome |
Q27003271 | MicroRNA regulation of T-lymphocyte immunity: modulation of molecular networks responsible for T-cell activation, differentiation, and development |
Q35487297 | MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines |
Q29614237 | MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer |
Q39494676 | MicroRNA-101 inhibits growth of epithelial ovarian cancer by relieving chromatin-mediated transcriptional repression of p21(waf¹/cip¹). |
Q35523881 | MicroRNA-125b potentiates macrophage activation |
Q37625750 | MicroRNA-130b targets PTEN to mediate drug resistance and proliferation of breast cancer cells via the PI3K/Akt signaling pathway |
Q54284943 | MicroRNA-144 promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of PTEN. |
Q24648090 | MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA |
Q53205827 | MicroRNA-155 promotes apoptosis in SKOV3, A2780, and primary cultured ovarian cancer cells. |
Q24603354 | MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer |
Q33917538 | MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression |
Q39067776 | MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD. |
Q55418376 | MicroRNA-19b promotes the migration and invasion of ovarian cancer cells by inhibiting the PTEN/AKT signaling pathway. |
Q42367922 | MicroRNA-205-5p regulates the chemotherapeutic resistance of hepatocellular carcinoma cells by targeting PTEN/JNK/ANXA3 pathway |
Q34436329 | MicroRNA-20b promotes cell growth of breast cancer cells partly via targeting phosphatase and tensin homologue (PTEN). |
Q64233019 | MicroRNA-20b promotes proliferation of H22 hepatocellular carcinoma cells by targeting PTEN |
Q38737099 | MicroRNA-21 promotes cell proliferation, migration, and resistance to apoptosis through PTEN/PI3K/AKT signaling pathway in esophageal cancer |
Q28115504 | MicroRNA-214 Is Upregulated in Heart Failure Patients and Suppresses XBP1-Mediated Endothelial Cells Angiogenesis |
Q36392780 | MicroRNA-214 Mediates Isoproterenol-induced Proliferation and Collagen Synthesis in Cardiac Fibroblasts |
Q37078685 | MicroRNA-214 Reduces Insulin-like Growth Factor-1 (IGF-1) Receptor Expression and Downstream mTORC1 Signaling in Renal Carcinoma Cells |
Q47887382 | MicroRNA-214 protects cardiac myocytes against H2O2-induced injury |
Q35922278 | MicroRNA-214 suppresses growth and invasiveness of cervical cancer cells by targeting UDP-N-acetyl-α-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7. |
Q38751258 | MicroRNA-214 suppresses growth, migration and invasion through a novel target, high mobility group AT-hook 1, in human cervical and colorectal cancer cells |
Q36336233 | MicroRNA-214 suppresses the proliferation of human hepatocellular carcinoma cells by targeting E2F3. |
Q24597730 | MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN |
Q24648241 | MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1 |
Q24645663 | MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer |
Q38858232 | MicroRNA-222 promotes human non-small cell lung cancer H460 growth by targeting p27. |
Q36304803 | MicroRNA-26b Modulates the NF-κB Pathway in Alveolar Macrophages by Regulating PTEN. |
Q33843200 | MicroRNA-382 induced by HIF-1α is an angiogenic miR targeting the tumor suppressor phosphatase and tensin homolog |
Q35441996 | MicroRNA-383 regulates the apoptosis of tumor cells through targeting Gadd45g |
Q57786973 | MicroRNA-423 promotes proliferation, migration and invasion and induces chemoresistance of endometrial cancer cells |
Q38960629 | MicroRNA-449a reduces cell survival and enhances cisplatin-induced cytotoxicity via downregulation of NOTCH1 in ovarian cancer cells |
Q89475347 | MicroRNA-498 promotes proliferation and migration by targeting the tumor suppressor PTEN in breast cancer cells |
Q100477224 | MicroRNA-572/hMOF/Sirt6 regulates the progression of ovarian cancer |
Q36394758 | MicroRNA-98 and microRNA-214 post-transcriptionally regulate enhancer of zeste homolog 2 and inhibit migration and invasion in human esophageal squamous cell carcinoma |
Q37377527 | MicroRNA-Mediated Down-Regulation of Apoptosis Signal-Regulating Kinase 1 (ASK1) Attenuates the Apoptosis of Human Mesenchymal Stem Cells (MSCs) Transplanted into Infarcted Heart |
Q33764106 | MicroRNA-mRNA functional pairs for cisplatin resistance in ovarian cancer cells |
Q39382756 | MicroRNA-mediated drug resistance in ovarian cancer |
Q35207545 | MicroRNA100 inhibits self-renewal of breast cancer stem-like cells and breast tumor development |
Q26822743 | MicroRNA: a new and promising potential biomarker for diagnosis and prognosis of ovarian cancer |
Q38172970 | MicroRNA: a prognostic biomarker and a possible druggable target for circumventing multidrug resistance in cancer chemotherapy |
Q33809305 | MicroRNAs MiR-17, MiR-20a, and MiR-106b act in concert to modulate E2F activity on cell cycle arrest during neuronal lineage differentiation of USSC. |
Q36602853 | MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies |
Q45944835 | MicroRNAs and complex diseases: from experimental results to computational models. |
Q38174308 | MicroRNAs and the cancer phenotype: profiling, signatures and clinical implications |
Q37722649 | MicroRNAs and their role in gynecological tumors |
Q94046968 | MicroRNAs as Key Regulators of Ovarian Cancers |
Q37432291 | MicroRNAs couple cell fate and developmental timing in retina |
Q58923813 | MicroRNAs in Cancer Drug Resistance and Drug Sensitivity |
Q35832148 | MicroRNAs in apoptosis, autophagy and necroptosis |
Q26823360 | MicroRNAs in breast cancer initiation and progression |
Q38223219 | MicroRNAs in cancer stem cells: current status and future directions |
Q39333266 | MicroRNAs in gynecological cancers: Small molecules with big implications |
Q33796565 | MicroRNAs in ovarian carcinomas |
Q38003048 | MicroRNAs in pancreatic cancer metabolism |
Q39950193 | MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease |
Q38086010 | MicroRNAs regulate both epithelial-to-mesenchymal transition and cancer stem cells |
Q24618771 | MicroRNAs: control and loss of control in human physiology and disease |
Q35673637 | MicroRNAs: short non-coding players in cancer chemoresistance. |
Q92582088 | MicroRNA‑214 suppresses the viability, migration and invasion of human colorectal carcinoma cells via targeting transglutaminase 2 |
Q93111083 | MicroRNA‑608 sensitizes non‑small cell lung cancer cells to cisplatin by targeting TEAD2 |
Q64234430 | Micromanaging aerobic respiration and glycolysis in cancer cells |
Q34108602 | Micromarkers: miRNAs in cancer diagnosis and prognosis. |
Q23916204 | Microprocessor of microRNAs: regulation and potential for therapeutic intervention |
Q35135678 | Minireview: The roles of small RNA pathways in reproductive medicine |
Q37328836 | Minireview: epigenetic changes in ovarian cancer. |
Q42215256 | Modulation of chemoresponsiveness to platinum-based agents by microRNAs in cancer |
Q38580177 | Molecular Regulation of Parturition: A Myometrial Perspective |
Q35116008 | Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo. |
Q33718304 | Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines |
Q38832323 | Molecular diagnosis and molecular profiling to detect treatment-resistant ovarian cancer |
Q37702543 | Molecular epigenetics in the management of ovarian cancer: are we investigating a rational clinical promise? |
Q37982453 | Molecular mechanisms of cisplatin resistance in bladder cancer. |
Q48274587 | Molecular mechanisms of drug resistance in ovarian cancer. |
Q34586019 | Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma |
Q36862768 | Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response |
Q36908289 | Myocardial AKT: the omnipresent nexus |
Q36390287 | NRP1 is targeted by miR-130a and miR-130b, and is associated with multidrug resistance in epithelial ovarian cancer based on integrated gene network analysis |
Q31040165 | Network analysis of microRNAs and their regulation in human ovarian cancer |
Q37725910 | New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives |
Q37837735 | New players in ovarian cancer |
Q55237582 | Non-Coding Transcript Heterogeneity in Mesothelioma: Insights from Asbestos-Exposed Mice. |
Q57815805 | Non-coding RNA NEAT1/miR-214-3p contribute to doxorubicin resistance of urothelial bladder cancer preliminary through the Wnt/β-catenin pathway |
Q38885498 | Noncoding RNAs Regulating Cancer Signaling Network |
Q36571216 | Noncoding RNAs and Cancer. |
Q38885495 | Noncoding RNAs in Therapeutic Resistance of Cancer |
Q96609205 | Noncoding RNAs: the shot callers in tumor immune escape |
Q42218359 | Nongenomic Mechanisms of PTEN Regulation |
Q36209417 | Novel classes of non-coding RNAs and cancer |
Q39096424 | Nucleoside analog inhibits microRNA-214 through targeting heat-shock factor 1 in human epithelial ovarian cancer. |
Q35837949 | Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways |
Q48124146 | Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells |
Q38013671 | Ovarian cancer stem cells: elusive targets for chemotherapy |
Q36540852 | Overexpression of miR-214-3p in esophageal squamous cancer cells enhances sensitivity to cisplatin by targeting survivin directly and indirectly through CUG-BP1. |
Q50236474 | Overexpression of microRNA-15 increases the chemosensitivity of colon cancer cells to 5-fluorouracil and oxaliplatin by inhibiting the nuclear factor-κB signalling pathway and inducing apoptosis. |
Q28396088 | Overexpression of secretagogin inhibits cell apoptosis and induces chemoresistance in small cell lung cancer under the regulation of miR-494 |
Q28383083 | PI3K/PTEN signaling in angiogenesis and tumorigenesis |
Q45318299 | PTEN Regulation |
Q39644716 | PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors |
Q34824223 | PTEN hamartoma tumor syndromes. |
Q42412809 | PTEN in liver diseases and cancer |
Q35056451 | PTEN is a negative regulator of NK cell cytolytic function. |
Q50299118 | PTEN mRNA translation is negatively regulated by microRNAs |
Q82600359 | PTEN promoter methylation and LOH of 10q22-23 locus in PTEN expression of ovarian clear cell adenocarcinomas |
Q37420213 | Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis |
Q37346198 | Pharmaco(epi)genomics in ovarian cancer |
Q28384799 | Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and PH domain and leucine-rich repeat phosphatase cross-talk (PHLPP) in cancer cells and in transforming growth factor β-activated stem cells |
Q39392171 | Phospho-ΔNp63α-dependent regulation of autophagic signaling through transcription and micro-RNA modulation |
Q26798324 | Phytochemicals modulate carcinogenic signaling pathways in breast and hormone-related cancers |
Q38879511 | Pivotal MicroRNAs in Melanoma: A Mini-Review |
Q35578546 | Population differences in microRNA expression and biological implications |
Q37308227 | Potential regulatory functions of microRNAs in the ovary |
Q21245724 | Potential role of miR-9 and miR-223 in recurrent ovarian cancer |
Q54117850 | Potential tumor suppressing role of microRNA-545 in epithelial ovarian cancer. |
Q34803840 | Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma |
Q35232213 | Potentially predictive microRNAs of gastric cancer with metastasis to lymph node |
Q36889793 | Prediction value of miR-483 and miR-214 in prognosis and multidrug resistance of esophageal squamous cell carcinoma |
Q33651583 | Prognostic and predictive biomarkers: tools in personalized oncology |
Q34086636 | Prognostic biomarkers in ovarian cancer |
Q36642134 | Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer |
Q36077545 | Prognostic significance of miR-215 in colon cancer |
Q39219310 | Promoter methylation of the SALL2 tumor suppressor gene in ovarian cancers |
Q42129357 | Promoter region methylation and loss of protein expression of PTEN and significance in cervical cancer |
Q94526169 | Psoralen Suppresses Cisplatin-Mediated Resistance and Induces Apoptosis of Gastric Adenocarcinoma by Disruption of the miR196a-HOXB7-HER2 Axis |
Q49378677 | Pterostilbene increases PTEN expression through the targeted downregulation of microRNA-19a in hepatocellular carcinoma |
Q34221132 | RAB8 enhances TMEM205-mediated cisplatin resistance |
Q36034189 | RBMMMDA: predicting multiple types of disease-microRNA associations |
Q38432883 | RNA-based ovarian cancer research from 'a gene to systems biomedicine' perspective. |
Q35679353 | Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health |
Q37984588 | Recent trends in cancer drug resistance reversal strategies using nanoparticles |
Q47828965 | Reciprocal regulation of miR-214 and PTEN by high glucose regulates renal glomerular mesangial and proximal tubular epithelial cell hypertrophy and matrix expansion. |
Q35067942 | Reduced miR-126 expression facilitates angiogenesis of gastric cancer through its regulation on VEGF-A |
Q34478004 | Regulation of NANOG in cancer cells |
Q58754551 | Regulation of PTEN expression by noncoding RNAs |
Q45318301 | Regulation of PTEN mRNA translation |
Q35034340 | Regulation of cancer metastasis by cell-free miRNAs |
Q33892003 | Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors |
Q24623118 | Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition |
Q34283589 | Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research |
Q34197212 | Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2. |
Q34089030 | Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis |
Q91949964 | Relations between approved platinum drugs and non-coding RNAs in mesothelioma |
Q64270008 | Relationship between microRNA-27a and efficacy of neoadjuvant chemotherapy in gastric cancer and its mechanism in gastric cancer cell growth and metastasis |
Q41785826 | Relevance of Rabbit VX2 Tumor Model for Studies on Human Hepatocellular Carcinoma: A MicroRNA-Based Study |
Q36460311 | Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel |
Q36152814 | Retracted: MicroRNA-20b (miR-20b) Promotes the Proliferation, Migration, Invasion, and Tumorigenicity in Esophageal Cancer Cells via the Regulation of Phosphatase and Tensin Homologue Expression |
Q35113163 | Retracted: MicroRNA-214 Suppresses Oncogenesis and Exerts Impact on Prognosis by Targeting PDRG1 in Bladder Cancer |
Q37441874 | Ribonucleases as potential modalities in anticancer therapy |
Q35062972 | Role of Dicer in female fertility |
Q33703270 | Role of Epigenetics in Uveal Melanoma |
Q24647234 | Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells |
Q37961734 | Role of epigenomics in ovarian and endometrial cancers |
Q34230585 | Role of miR-148a in hepatitis B associated hepatocellular carcinoma. |
Q39387335 | Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells. |
Q39261923 | Role of miRNAs in neuronal differentiation from human embryonic stem cell-derived neural stem cells |
Q92636165 | Role of microRNAs as Clinical Cancer Biomarkers for Ovarian Cancer: A Short Overview |
Q38258014 | Role of microRNAs in cancers of the female reproductive tract: insights from recent clinical and experimental discovery studies |
Q26770485 | Role of microRNAs in chemoresistance |
Q39621434 | Role of ribosomal protein RPS2 in controlling let-7a expression in human prostate cancer |
Q38346740 | Role of the AKT pathway in microRNA expression of human U251 glioblastoma cells |
Q34599169 | Roles and mechanism of miR-199a and miR-125b in tumor angiogenesis |
Q98771139 | Roles of microRNAs in Ovarian Cancer Tumorigenesis: Two Decades Later, What Have We Learned? |
Q34966603 | Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging |
Q90043990 | SOX2 mediates cisplatin resistance in small-cell lung cancer with downregulated expression of hsa-miR-340-5p |
Q58693575 | STAT3 regulated promotes ovarian cancer proliferation and cisplatin resistance |
Q34999442 | Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection |
Q35036873 | Scleral micro-RNA signatures in adult and fetal eyes |
Q89583081 | Screening of potential miRNA therapeutics for the prevention of multi-drug resistance in cancer cells |
Q52562510 | Searching for new biomarkers in ovarian cancer patients: Rationale and design of a retrospective study under the Mermaid III project. |
Q39353348 | Selection and validation of miRNAs as normalizers for profiling expression of microRNAs isolated from thyroid fine needle aspiration smears. |
Q37190115 | Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis |
Q93199665 | Serum microRNAs as potential new biomarkers for cisplatin resistance in gastric cancer patients |
Q35070602 | Shielding the messenger (RNA): microRNA-based anticancer therapies |
Q36768990 | Silibinin-Induced Apoptosis and Downregulation of MicroRNA-21 and MicroRNA-155 in MCF-7 Human Breast Cancer Cells |
Q38547893 | Small RNAs: Their Possible Roles in Reproductive Failure |
Q34425882 | Small players with big roles: microRNAs as targets to inhibit breast cancer progression |
Q37906461 | Stem cell microRNAs in senescence and immortalization: novel players in cancer therapy |
Q38975225 | Strategic targeting of the PI3K-NFκB axis in cisplatin-resistant NSCLC. |
Q33780712 | Strengths and limitations of laboratory procedures for microRNA detection |
Q36270963 | Suppression of miR-199a maturation by HuR is crucial for hypoxia-induced glycolytic switch in hepatocellular carcinoma |
Q61811539 | Suppression of miR-21-3p enhances TRAIL-mediated apoptosis in liver cancer stem cells by suppressing the PI3K/Akt/Bad cascade via regulating PTEN |
Q33862088 | Sweating the small stuff: microRNAs and genetic changes define pancreatic cancer |
Q36042091 | Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors |
Q38927716 | TRPM3 and miR-204 establish a regulatory circuit that controls oncogenic autophagy in clear cell renal cell carcinoma. |
Q33927452 | TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214. |
Q37170030 | Targeting cancer stem cells: emerging role of Nanog transcription factor |
Q37392708 | Targeting miR-21-3p inhibits proliferation and invasion of ovarian cancer cells |
Q34208986 | Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. |
Q36545132 | Targeting of RUNX3 by miR-130a and miR-495 cooperatively increases cell proliferation and tumor angiogenesis in gastric cancer cells |
Q36992190 | Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Νew trends in the development of miRNA therapeutic strategies in oncology (Review). |
Q38841574 | Targeting the Wnt-Regulatory Protein CTNNBIP1 by microRNA-214 Enhances the Stemness and Self-Renewal of Cancer Stem-Like Cells in Lung Adenocarcinomas |
Q29615809 | Targeting the phosphoinositide 3-kinase pathway in cancer |
Q28472826 | Telomere shortening sensitizes cancer cells to selected cytotoxic agents: in vitro and in vivo studies and putative mechanisms |
Q38975570 | The Diagnostic and Prognostic Potential of microRNAs in Epithelial Ovarian Carcinoma |
Q26776527 | The PTEN tumor suppressor gene and its role in lymphoma pathogenesis |
Q37506648 | The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma |
Q24657924 | The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo |
Q36927913 | The Role of microRNAs in the Tumorigenesis of Ovarian Cancer |
Q92280511 | The Roles of miRNAs in Medulloblastoma: A Systematic Review |
Q49164136 | The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint |
Q38203092 | The clinical and diagnostic role of microRNAs in ovarian carcinoma |
Q35541834 | The combination of thioxodihydroquinazolinones and platinum drugs reverses platinum resistance in tumor cells by inducing mitochondrial apoptosis independent of Bax and Bak |
Q34014208 | The cytotoxic ribonuclease onconase targets RNA interference (siRNA). |
Q33579675 | The expression and functions of microRNAs in pancreatic adenocarcinoma and hepatocellular carcinoma |
Q24606503 | The functional significance of microRNA-145 in prostate cancer |
Q92295239 | The influence of long non-coding RNAs on the response to chemotherapy in ovarian cancer |
Q39029645 | The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer |
Q37385514 | The mammalian ovary from genesis to revelation |
Q37578813 | The miR-106b~25 cluster promotes bypass of doxorubicin-induced senescence and increase in motility and invasion by targeting the E-cadherin transcriptional activator EP300. |
Q36091102 | The miR-199-dynamin regulatory axis controls receptor-mediated endocytosis. |
Q26799353 | The miR-200 Family: Versatile Players in Epithelial Ovarian Cancer |
Q42371676 | The miR-200 family in ovarian cancer. |
Q42700734 | The miR-486-5p plays a causative role in prostate cancer through negative regulation of multiple tumor suppressor pathways |
Q36299753 | The miRNA-drug resistance connection: a new era of personalized medicine using noncoding RNA begins |
Q38117120 | The microRNA regulation of stem cells |
Q37703901 | The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment |
Q87123309 | The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma: a retrospective cohort study |
Q35933934 | The prognostic value of the miR-200 family in ovarian cancer: a meta-analysis. |
Q64237748 | The role and mechanisms of action of microRNAs in cancer drug resistance |
Q37270446 | The role of PTEN signaling perturbations in cancer and in targeted therapy |
Q26851256 | The role of microRNA in head and neck cancer: current knowledge and perspectives |
Q37801505 | The role of microRNA in modulating myocardial ischemia-reperfusion injury |
Q38027966 | The role of microRNA in the response to cisplatin treatment |
Q37601781 | The role of microRNAs in endometriosis and associated reproductive conditions |
Q34253436 | The role of microRNAs in ovarian cancer |
Q37293916 | The role of microRNAs in ovarian cancer initiation and progression |
Q91639454 | The roles of curcumin in regulating the tumor immunosuppressive microenvironment |
Q36008522 | The transcription factor GCF2 is an upstream repressor of the small GTPAse RhoA, regulating membrane protein trafficking, sensitivity to doxorubicin, and resistance to cisplatin |
Q38210867 | Therapeutic potential of microRNA let-7: tumor suppression or impeding normal stemness. |
Q37837732 | Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. |
Q46973951 | Thyroid hormone inhibits growth of hepatoma cells through induction of miR-214. |
Q33721556 | Trail resistance induces epithelial-mesenchymal transition and enhances invasiveness by suppressing PTEN via miR-221 in breast cancer |
Q34648126 | Transcription factor-microRNA-target gene networks associated with ovarian cancer survival and recurrence |
Q37685062 | Transformation of human ovarian surface epithelial cells by Krüppel-like factor 8. |
Q37727428 | Triptolide inhibits the proliferation of cells from lymphocytic leukemic cell lines in association with downregulation of NF-κB activity and miR-16-1*. |
Q83840777 | Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients |
Q24652478 | Twist-1 regulates the miR-199a/214 cluster during development |
Q37618382 | Upregulation of MiR-205 transcriptionally suppresses SMAD4 and PTEN and contributes to human ovarian cancer progression |
Q49263988 | Upregulation of miR-146a increases cisplatin sensitivity of the non-small cell lung cancer A549 cell line by targeting JNK-2. |
Q28539122 | Upregulation of miR-21 in cisplatin resistant ovarian cancer via JNK-1/c-Jun pathway |
Q35290367 | Upregulation of microRNA-125b contributes to leukemogenesis and increases drug resistance in pediatric acute promyelocytic leukemia |
Q89144265 | Upregulation of microRNA-3129 suppresses epithelial ovarian cancer through CD44 |
Q38792755 | Upregulation of microRNA-375 increases the cisplatin-sensitivity of human gastric cancer cells by regulating ERBB2. |
Q35215772 | Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway |
Q38941347 | VEGF-mediated suppression of cell proliferation and invasion by miR-410 in osteosarcoma |
Q58580750 | Vitamin D and its receptor polymorphisms: New possible prognostic biomarkers in leukemias |
Q38272241 | Warburg meets non-coding RNAs: the emerging role of ncRNA in regulating the glucose metabolism of cancer cells |
Q34122840 | Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening |
Q41390518 | Wound fluids affect miR-21, miR-155 and miR-221 expression in breast cancer cell lines, and this effect is partially abrogated by intraoperative radiation therapy treatment |
Q55450209 | [Advances in tumor chemo-resistance regulated by MicroRNA]. |
Q53242728 | [Screening and identification of microRNAs related to acquired gefitinib-resistance in lung adenocarcinoma cell lines]. |
Q50095469 | cis-Platinum pro-drug-attached CuFeS2 nanoplates for in vivo photothermal/photoacoustic imaging and chemotherapy/photothermal therapy of cancer. |
Q47134084 | let-7b and let-7c microRNAs promote histone H2B ubiquitylation and inhibit cell migration by targeting multiple components of the H2B deubiquitylation machinery |
Q38952951 | miR-101 regulates expression of EZH2 and contributes to progression of and cisplatin resistance in epithelial ovarian cancer |
Q37548314 | miR-106a represses the Rb tumor suppressor p130 to regulate cellular proliferation and differentiation in high-grade serous ovarian carcinoma. |
Q39493576 | miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1. |
Q34195513 | miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222 |
Q91971092 | miR-130a-3p inhibition protects against renal fibrosis in vitro via the TGF-β1/Smad pathway by targeting SnoN |
Q39439864 | miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response |
Q34436363 | miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells |
Q50353125 | miR-144 Potentially Suppresses Proliferation and Migration of Ovarian Cancer Cells by Targeting RUNX1. |
Q37144041 | miR-144 reverses chemoresistance of hepatocellular carcinoma cell lines by targeting Nrf2-dependent antioxidant pathway |
Q35013059 | miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors |
Q39025625 | miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6. |
Q46272050 | miR-148a-3p Mediates Notch Signaling to Promote the Differentiation and M1 Activation of Macrophages |
Q23916198 | miR-190-mediated downregulation of PHLPP contributes to arsenic-induced Akt activation and carcinogenesis |
Q34607960 | miR-199a-5p Is upregulated during fibrogenic response to tissue injury and mediates TGFbeta-induced lung fibroblast activation by targeting caveolin-1 |
Q59795094 | miR-205-5p Mediated Downregulation of PTEN Contributes to Cisplatin Resistance in C13K Human Ovarian Cancer Cells |
Q89511641 | miR-20b and miR-451a Are Involved in Gastric Carcinogenesis through the PI3K/AKT/mTOR Signaling Pathway: Data from Gastric Cancer Patients, Cell Lines and Ins-Gas Mouse Model |
Q47380679 | miR-20b promotes cellular proliferation and migration by directly regulating phosphatase and tensin homolog in prostate cancer |
Q28854274 | miR-21 and miR-214 are consistently modulated during renal injury in rodent models |
Q46209823 | miR-214 and hypoxia down-regulate Necl-2/CADM1 and enhance ErbB2/ErbB3 signaling |
Q27023833 | miR-214 as a key hub that controls cancer networks: small player, multiple functions |
Q64355502 | miR-214 is Stretch-Sensitive in Aortic Valve and Inhibits Aortic Valve Calcification |
Q50299117 | miR-214 microRNA binds PTEN mRNA |
Q36192032 | miR-214 promotes osteoclastogenesis by targeting Pten/PI3k/Akt pathway |
Q44424639 | miR-214 promotes tumorigenesis by targeting lactotransferrin in nasopharyngeal carcinoma |
Q34316430 | miR-214 targets ATF4 to inhibit bone formation. |
Q47430029 | miR-214 targets the PTEN-mediated PI3K/Akt signaling pathway and regulates cell proliferation and apoptosis in ovarian cancer |
Q38721645 | miR-214-5p Targets ROCK1 and Suppresses Proliferation and Invasion of Human Osteosarcoma Cells |
Q50099869 | miR-214-Dependent Increase of PHLPP2 Levels Mediates the Impairment of Insulin-Stimulated Akt Activation in Mouse Aortic Endothelial Cells Exposed to Methylglyoxal. |
Q36189350 | miR-214-mediated downregulation of RNF8 induces chromosomal instability in ovarian cancer cells |
Q38319595 | miR-214: a potential biomarker and therapeutic for different cancers |
Q21091130 | miR-22 forms a regulatory loop in PTEN/AKT pathway and modulates signaling kinetics |
Q35438578 | miR-23b targets proline oxidase, a novel tumor suppressor protein in renal cancer |
Q88190776 | miR-3188 Regulates Cell Proliferation, Apoptosis, and Migration in Breast Cancer by Targeting TUSC5 and Regulating the p38 MAPK Signaling Pathway |
Q39342904 | miR-34a is downregulated in cis-diamminedichloroplatinum treated sinonasal squamous cell carcinoma patients with poor prognosis. |
Q58572436 | miR-34a targets BCL-2 to suppress the migration and invasion of sinonasal squamous cell carcinoma |
Q90205451 | miR-375-3p suppresses tumorigenesis and partially reverses chemoresistance by targeting YAP1 and SP1 in colorectal cancer cells |
Q92094478 | miR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR |
Q41698288 | miR-494 up-regulates the PI3K/Akt pathway via targetting PTEN and attenuates hepatic ischemia/reperfusion injury in a rat model |
Q39095757 | miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A). |
Q37742282 | miR-495 promotes the chemoresistance of SCLC through the epithelial-mesenchymal transition via Etk/BMX |
Q40800119 | miR-7 modulates chemoresistance of small cell lung cancer by repressing MRP1/ABCC1. |
Q40328958 | miR-718 represses proinflammatory cytokine production through targeting phosphatase and tensin homolog (PTEN). |
Q37734627 | miR-9 functions as a tumor inhibitor of cell proliferation in epithelial ovarian cancer through targeting the SDF-1/CXCR4 pathway |
Q26992374 | miRNA and mammalian male germ cells |
Q37295492 | miRNA profiling along tumour progression in ovarian carcinoma |
Q40466065 | miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma. |
Q37697194 | miRNA-200a/c as potential biomarker in epithelial ovarian cancer (EOC): evidence based on miRNA meta-signature and clinical investigations |
Q39289196 | miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence |
Q28742532 | miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors |
Q39432311 | miRNAs and ovarian cancer: An overview |
Q38633144 | miRNAs and ovarian cancer: a miRiad of mechanisms to induce cisplatin drug resistance |
Q38031424 | miRNAs as biomarkers in prostate cancer |
Q38366731 | miRNAs as prognostic and therapeutic tools in epithelial ovarian cancer |
Q38003705 | miRNAs in breast cancer: ready for real time? |
Q33827750 | miRNAs in human cancer. |
Q37608111 | miRNAs modulate the drug response of tumor cells |
Q38667018 | microRNA and Ovarian Cancer |
Q33954625 | microRNA and cancer |
Q33780259 | microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma |
Q38729639 | microRNA-137 promotes apoptosis in ovarian cancer cells via the regulation of XIAP. |
Q34993968 | microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. |
Q41972639 | microRNA-214 functions as a tumor suppressor in human colon cancer via the suppression of ADP-ribosylation factor-like protein 2. |
Q34049130 | microRNA-214-mediated UBC9 expression in glioma |
Q34427403 | microRNA-222 targeting PTEN promotes neurite outgrowth from adult dorsal root ganglion neurons following sciatic nerve transection |
Q26778918 | microRNAs as pharmacogenomic biomarkers for drug efficacy and drug safety assessment |
Q37592046 | microRNAs in gliomas: small regulators of a big problem |